Surrozen, Inc. Files 8-K for Material Agreement
Ticker: SRZNW · Form: 8-K · Filed: Aug 29, 2025 · CIK: 1824893
| Field | Detail |
|---|---|
| Company | Surrozen, Inc./De (SRZNW) |
| Form Type | 8-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $50.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-filing
Related Tickers: SRZN
TL;DR
Surrozen (SRZN) filed an 8-K for a material definitive agreement. Big news coming.
AI Summary
On August 29, 2025, Surrozen, Inc. filed an 8-K report detailing a material definitive agreement. The company, formerly known as Consonance-HFW Acquisition Corp., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates Surrozen, Inc. has entered into a significant agreement, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.
Key Numbers
- 001-39635 — SEC File Number (Identifies the company's filing with the SEC)
- 30-1374889 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Surrozen, Inc. (company) — Registrant
- Consonance-HFW Acquisition Corp. (company) — Former company name
- August 29, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the nature of the material definitive agreement filed by Surrozen, Inc.?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the excerpt.
When was Surrozen, Inc. formerly known as?
Surrozen, Inc. was formerly known as Consonance-HFW Acquisition Corp.
In which state is Surrozen, Inc. incorporated?
Surrozen, Inc. is incorporated in Delaware.
What is the SIC code for Surrozen, Inc.?
The Standard Industrial Classification (SIC) code for Surrozen, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the principal business address of Surrozen, Inc.?
The principal business address of Surrozen, Inc. is 171 Oyster Point Blvd, Suite 400, South San Francisco, California, 94080.
Filing Stats: 939 words · 4 min read · ~3 pages · Grade level 11.3 · Accepted 2025-08-29 16:58:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SRZN The Nasdaq
- $50.0 million — g an aggregate offering amount of up to $50.0 million (the "Shares"). We are not obligated
Filing Documents
- srzn-20250829.htm (8-K) — 57KB
- srzn-ex1_1.htm (EX-1.1) — 392KB
- srzn-ex5_1.htm (EX-5.1) — 24KB
- img200110477_0.jpg (GRAPHIC) — 88KB
- 0000950170-25-112253.txt ( ) — 796KB
- srzn-20250829.xsd (EX-101.SCH) — 45KB
- srzn-20250829_htm.xml (XML) — 6KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On August 29, 2025, Surrozen, Inc. entered into a Sales Agreement (the "Sales Agreement") with TD Securities (USA) LLC ("TD Cowen"). Under the Sales Agreement, we may offer and sell, from time to time, through TD Cowen as our sales agent and/or principal, shares of our common stock, par value $0.0001 per share ("Common Stock"), having an aggregate offering amount of up to $50.0 million (the "Shares"). We are not obligated to sell any Shares under the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, TD Cowen will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell the Shares from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we may specify, subject to certain limitations. Under the Sales Agreement, TD Cowen may sell the Shares in negotiated transactions, including block trades or block sales, or by any method that is deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including without limitation sales made through the Nasdaq Capital Market or on any other existing trading market for the Common Stock, or by any other method permitted by law. We will pay TD Cowen a commission of up to 3.0% of the gross sales proceeds of any Shares sold through TD Cowen under the Sales Agreement. We have also provided TD Cowen with customary indemnification and contribution rights. The Sales Agreement may be terminated by us or TD Cowen upon written notice to the other party in accordance with the terms of the Sales Agreement. The offering of the Shares pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement in accordance with its terms. The issuance and sale, if any, of the Shares under the Sales Agreement will be made pursuant to our Reg
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Sales Agreement, dated August 29, 2025, by and between Surrozen, Inc. and TD Securities (USA) LLC. 5.1 Legal Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SURROZEN, INC. Date: August 29, 2025 By: /s/ Charles Williams Name: Charles Williams Title: Chief Financial Officer, Chief Operating Officer and Corporate Secretary